What the FDA labels say about taking them together
Panitumumab and sotorasib
Panitumumab's FDA label of June 23, 2026 names sotorasib in its warnings and precautions section, and sotorasib's label names panitumumab too.
Check it at the source: the panitumumab FDA label on DailyMed (effective June 23, 2026, Amgen, Inc); the sotorasib FDA label on DailyMed (effective January 22, 2025).
What does the panitumumab label say about sotorasib?
Panitumumab label, warnings and precautionsIn 126 patients receiving Vectibix in combination with sotorasib across clinical studies, dermatologic toxicities occurred in 94%, including Grade 3 (16%) of patients.
Source: FDA drug label (Vectibix), Amgen, Inc, effective June 23, 2026 (SPL set e0fa4bca-f245-4d92-ae29-b0c630a315c2), via openFDA; the full label on DailyMed
What does the sotorasib label say about panitumumab?
Sotorasib label, warnings and precautionsIn the pooled safety population of patients with CRC who received LUMAKRAS 960 mg in combination with panitumumab [see Adverse Reactions (6.1) ], hepatotoxicity occurred in 15% of patients, of which 4.8% were Grade 3.
Source: FDA drug label (LUMAKRAS), Amgen Inc, effective January 22, 2025 (SPL set c80a362c-7ac3-4894-a076-0691e68ef8c1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Panitumumab | Sotorasib | |
|---|---|---|
| Labeled for | Colorectal cancer | Lung cancer, Colorectal cancer |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once